Biological Therapy in Inflammatory Bowel Disease Patients Partly Restores Intestinal Innate Lymphoid Cell Subtype Equilibrium

Brecht Creyns(KU Leuven), Christine Breynaert(KU Leuven), Jan Ceuppens, Séverine Vermeire(KU Leuven), Marc Ferrante(Universitair Ziekenhuis Leuven), Bram Verstockt(Universitair Ziekenhuis Leuven), Vera Ballet(KU Leuven), Gert Van Assche(KU Leuven), Jonathan Cremer(KU Leuven), Inge Jacobs(KU Leuven), Tim Vanuytsel(Universitair Ziekenhuis Leuven), Roselien Vandecasteele(KU Leuven)
Frontiers in Immunology
August 27, 2020
10.3389/fimmu.2020.01847
Cited by 40

Related Papers

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
A decrease of the butyrate-producing species <i>Roseburia hominis</i> and <i>Faecalibacterium prausnitzii</i> defines dysbiosis in patients with ulcerative colitis
|Gut|2013|1.9k
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications
|Journal of Crohn s and Colitis|2018|1.8k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k